OZEMPIC (Novo Nordisk Pharmaceuticals Pty Ltd)
Product name
OZEMPIC
Date registered
Evaluation commenced
Decision date
Approval time
197 (255 working days)
Active ingredients
Semaglutide
Registration type
EOI
Indication
Ozempic is now also indicated as an adjunct to standard of care therapy to reduce the risk of sustained decline of kidney function and to reduce the risk of cardiovascular death in adults with type 2 diabetes and chronic kidney disease